Organization
University of Washington/Fred Hutchinson Cancer Research Center
3 abstracts
Abstract
Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.Org: University of Chicago, H. Lee Moffitt Cancer Center and Research Institute, City of Hope National Medical Center, University of Washington/Fred Hutchinson Cancer Research Center, University of Colorado Cancer Center,
Abstract
Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors.Org: University of Washington/Fred Hutchinson Cancer Research Center, University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Sarah Cannon Research Institute at HealthONE, University of Michigan Rogel Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Incidental discovery of second primary malignancies in patients diagnosed with breast cancer: An institutional case series.Org: Temple University Hospital, Philadelphia, PA, University of Washington/Fred Hutchinson Cancer Research Center, University of Washington and Fred Hutchinson Cancer Research Centre, University of Washington, Cancer Vaccine Institute, Fred Hutchinson Cancer Research Center,